Cargando…
Insights on prospects of nano-siRNA based approaches in treatment of Cancer
siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452808/ https://www.ncbi.nlm.nih.gov/pubmed/36091772 http://dx.doi.org/10.3389/fphar.2022.985670 |
_version_ | 1784784995487842304 |
---|---|
author | Goyal, Rajat Chopra, Hitesh singh, Inderbir Dua, Kamal Gautam, Rupesh K. |
author_facet | Goyal, Rajat Chopra, Hitesh singh, Inderbir Dua, Kamal Gautam, Rupesh K. |
author_sort | Goyal, Rajat |
collection | PubMed |
description | siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications. |
format | Online Article Text |
id | pubmed-9452808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94528082022-09-09 Insights on prospects of nano-siRNA based approaches in treatment of Cancer Goyal, Rajat Chopra, Hitesh singh, Inderbir Dua, Kamal Gautam, Rupesh K. Front Pharmacol Pharmacology siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9452808/ /pubmed/36091772 http://dx.doi.org/10.3389/fphar.2022.985670 Text en Copyright © 2022 Goyal, Chopra, singh, Dua and Gautam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Goyal, Rajat Chopra, Hitesh singh, Inderbir Dua, Kamal Gautam, Rupesh K. Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title | Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title_full | Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title_fullStr | Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title_full_unstemmed | Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title_short | Insights on prospects of nano-siRNA based approaches in treatment of Cancer |
title_sort | insights on prospects of nano-sirna based approaches in treatment of cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452808/ https://www.ncbi.nlm.nih.gov/pubmed/36091772 http://dx.doi.org/10.3389/fphar.2022.985670 |
work_keys_str_mv | AT goyalrajat insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer AT choprahitesh insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer AT singhinderbir insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer AT duakamal insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer AT gautamrupeshk insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer |